CFDE Data Portal | Search RPL7AP76

	Label	Description
	RPL7AP76 Gene (Entity type)	ENSG00000231995 - ribosomal protein L7a pseudogene 76
	GSE239844 crizotinib 11 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 0 v 8 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE126651 PRMT5 MTAP inhibition 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE156761 dopamine neuron 0 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE174745 dopamine neuron 1 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE142357 HDAC3 inhibition 1 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 7 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE116133 GSE116136 H-7 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 4 v 10 human dn Gene Set (Entity type)	A Gene Set from LINCS

RPL7AP76

ENSG00000231995 - ribosomal protein L7a pseudogene 76

GSE239844 crizotinib 11 v 2 human dn

A Gene Set from LINCS

GSE111247 temozolomide LN-308 0 v 8 human dn

A Gene Set from LINCS

GSE126651 PRMT5 MTAP inhibition 1 v 2 human up

A Gene Set from LINCS

GSE156761 dopamine neuron 0 v 2 human up

A Gene Set from LINCS

GSE174745 dopamine neuron 1 v 4 human up

A Gene Set from LINCS

GSE142357 HDAC3 inhibition 1 v 3 human dn

A Gene Set from LINCS

GSE195663 cisplatin 7 v 3 human dn

A Gene Set from LINCS

GSE116133 GSE116136 H-7 1 v 0 human up

A Gene Set from LINCS

GSE239844 crizotinib 4 v 10 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.